
Alfredo Perales-Puchalt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9529127/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas. Molecular Therapy - Oncolytics, 2022, 24, 218-229.	2.0	2
2	Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens. Genes and Cancer, 2021, 12, 51-64.	0.6	6
3	A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust TAcell generation. Molecular Therapy - Oncolytics, 2021, 21, 278-287.	2.0	7
4	BTN3A1 governs antitumor responses by coordinating $\hat{I}\pm\hat{I}^2$ and $\hat{I}^3\hat{I}$ T cells. Science, 2020, 369, 942-949.	6.0	83
5	Neutralization of hepatitis B virus by a novel DNA-encoded monoclonal antibody. Human Vaccines and Immunotherapeutics, 2020, 16, 2156-2164.	1.4	6
6	In Vivo Assembly of Nanoparticles Achieved through Synergy of Structureâ€Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. Advanced Science, 2020, 7, 1902802.	5.6	30
7	Nanoparticle Vaccines: In Vivo Assembly of Nanoparticles Achieved through Synergy of Structureâ€Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity (Adv.) Tj ETQ	q1 d.0.7 84	3114 rgBT /○
8	A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge. Cancer Immunology Research, 2019, 7, 174-182.	1.6	75
9	Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein–Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth. Vaccines, 2019, 7, 44.	2.1	11
10	Engineered transfer RNAs for suppression of premature termination codons. Nature Communications, 2019, 10, 822.	5.8	86
11	IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. Oncolmmunology, 2019, 8, e1515058.	2.1	14
12	Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models. Molecular Therapy, 2019, 27, 314-325.	3.7	27
13	Maternal telomere length is shorter in intrauterine growth restriction versus uncomplicated pregnancies, but not in the offspring or in IVF-conceived newborns. Reproductive BioMedicine Online, 2019, 38, 606-612.	1.1	3
14	DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity. JCI Insight, 2019, 4, .	2.3	36
15	Simplifying checkpoint inhibitor delivery through <i>in vivo</i> generation of synthetic DNA-encoded monoclonal antibodies (DMAbs). Oncotarget, 2019, 10, 13-16.	0.8	15
16	Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. Journal of Leukocyte Biology, 2018, 103, 799-805.	1.5	72
17	Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage <i>In Vivo</i> . Cancer Research, 2018, 78, 6363-6370.	0.4	45
18	SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Immunity, 2017, 46, 51-64.	6.6	122

#	Article	IF	CITATIONS
19	Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunology, Immunotherapy, 2017, 66, 1577-1588.	2.0	31
20	Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Cancer Discovery, 2017, 7, 72-85.	7.7	153
21	Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clinical Cancer Research, 2017, 23, 441-453.	3.2	77
22	Trametinib Drives T-cell–Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. Cancer Research, 2016, 76, 6253-6265.	0.4	46
23	IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. Cancer Research, 2016, 76, 2561-2572.	0.4	26
24	Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. Cell Reports, 2016, 14, 1774-1786.	2.9	89
25	ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell, 2015, 161, 1527-1538.	13.5	639
26	The Tumor Macroenvironment. Advances in Cancer Research, 2015, 128, 235-262.	1.9	48
27	Good prognosis of cerclage in cases of cervical insufficiency when intra-amniotic inflammation/infection is ruled out. Journal of Maternal-Fetal and Neonatal Medicine, 2015, 28, 1563-1568.	0.7	29
28	Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 194, 173-177.	0.5	42
29	Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation. Cancer Cell, 2015, 27, 27-40.	7.7	242
30	Mesothelin expression is associated with poor outcomes in breast cancer. Breast Cancer Research and Treatment, 2014, 147, 675-684.	1.1	42
31	Transforming Growth Factor Î ² -Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression. Immunity, 2014, 41, 427-439.	6.6	100
32	Angiogenic growth factors in maternal and fetal serum in concordant and discordant twin pregnancies. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 870-873.	0.7	10
33	Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer. Journal of Visualized Experiments, 2014, , .	0.2	20
34	Ovulation induction in women with polycystic ovary syndrome. Steroids, 2013, 78, 767-772.	0.8	46
35	The negative predictive value of cervical interleukin-6 for the risk assessment of preterm birth. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 1278-1281.	0.7	9
36	Low birth weight: is it related to assisted reproductive technology or underlying infertility?. Fertility and Sterility, 2013, 99, 303-310.	0.5	66

#	Article	IF	CITATIONS
37	The Effects of Acellular Dermal Matrix in Expander-Implant Breast Reconstruction after Total Skin-Sparing Mastectomy. Plastic and Reconstructive Surgery, 2013, 131, 278e-279e.	0.7	0
38	Threshold values of follicle count for the definition of PCO. Human Reproduction, 2012, 27, 1543-1543.	0.4	1
39	Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1363-1366.	0.7	45
40	Vaginal relapse after laparoscopic hysterectomy in early endometrial carcinoma: does the intrauterine manipulator affect the results?. Gynecological Surgery, 2012, 9, 461-463.	0.9	3
41	Éxito en el manejo conservador del acretismo placentario mediante embolización y metotrexato. Progresos En Obstetricia Y Ginecologia, 2012, 55, 80-84.	0.0	0
42	Effect of delayed umbilical cord clamping on blood gas analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 162, 21-23.	0.5	43
43	Reproductive medicine and inheritance of infertility by offspring: the role of fetal programming. Fertility and Sterility, 2011, 96, 536-545.	0.5	17
44	Cervical interleukin-6 as a predictive test for preterm delivery in symptomatic women: preliminary results. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 155, 14-18.	0.5	22
45	Cervical Interleukin-6 as a Predictive Test for Preterm Delivery in Symptomatic Women: Preliminary Results. Obstetrical and Gynecological Survey, 2011, 66, 391-392.	0.2	0
46	Masa anexial derecha con diagnóstico intraoperatorio de mucocele apendicular. A propósito de un caso. Clinica E Investigacion En Ginecologia Y Obstetricia, 2011, 38, 56-58.	0.1	1
47	Perioperative cesarean delivery morbidity among HIV-infected women under highly active antiretroviral treatment: a case-control study. European Journal of Obstetrics, Gynecology and	0.5	11